Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled, dose-response study of denosumab (AMG 162) in Japanese postmenopausal osteoporosis; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED | Results posted: 2010-01-27